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Abstract
Objective: The efficacy and reliability of prognostic scores has been described extensively for intensive care, but
their role for predicting mortality in intermediate care patients is uncertain. To provide more information in this field,
we have analyzed the performance of the Simplified Acute Physiology Score (SAPS) II and SAPS 3 in a single center
intermediate care unit (ImCU).
Materials and Methods: Cohort study with prospectively collected data from all patients admitted to a single center
ImCU in Pamplona, Spain, from April 2006 to April 2012. The SAPS II and SAPS 3 scores with respective predicted
mortality rates were calculated according to standard coefficients. Discrimination was evaluated by calculating the
area under receiver operating characteristic curve (AUROC) and calibration with the Hosmer-Lemeshow goodness of
fit test. Standardized mortality ratios (SMR) with 95% confidence interval (95% CI) were calculated for each model.
Results: The study included 607 patients. The observed in-hospital mortality was 20.1% resulting in a SMR of 0.87
(95% CI 0.73-1.04) for SAPS II and 0.56 (95% CI 0.47-0.67) for SAPS 3. Both scores showed acceptable
discrimination, with an AUROC of 0.76 (95% CI 0.71-0.80) for SAPS II and 0.75 (95% CI 0.71- 0.80) for SAPS 3.
Calibration curves showed similar performance based on Hosmer-Lemeshow goodness of fit C-test: (X2=12.9,
p=0.113) for SAPS II and (X2=4.07, p=0.851) for SAPS 3.
Conclusions: Although both scores overpredicted mortality, SAPS II showed better discrimination for patients
admitted to ImCU in terms of SMR.
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Introduction
Worldwide health care institutions try to give care based on
best-practice models with cost-effectiveness. In this scenario,
intermediate care units (ImCU) provide a rational and
proportional treatment between the intensive care and the
general ward.
Previous studies suggested that around 35% of intensive
care unit (ICU) admissions were for low risk patients that were
admitted mainly for monitoring purposes [1,2], while, in
contrast, some patients were treated on general wards when
they should receive more intensive care and monitoring [3]. As
a result, the development of intermediate care showed
encouraging results in terms of cost-containment and ICU
utilization, triage flexibility for acute patients and mortality rates
for hospital wards [3-10].
Nevertheless, the characteristics of the ImCUs and the type
and amount of services provided, varies depending on
resource availability, institutional infrastructure and the parent
health care system. Accordingly, the case mix population of
intermediate care may show great heterogeneity.
Characterization of these patients relies on the assessment
of their illness severity, using severity scores. Although the
performance of severity scores has been widely described in
ICU patients, the information in the setting of ImCU is very
limited [11-13]. The purpose of this study was to analyze the
performance of both, the Simplified Acute Physiology Score
(SAPS) II and SAPS 3 in a single center ImCU.
Materials and Methods
This study was performed at the Clínica Universidad de
Navarra, an academic medical center of 300 beds, in
Pamplona, Spain. Its ImCU is a 9-bed multi-purpose unit
adjacent to, but independent from, the mixed ICU. Each bed is
equipped with continuous telemetry, pulse oxymetry,
PLOS ONE | www.plosone.org 1 October 2013 | Volume 8 | Issue 10 | e77229
noninvasive arterial blood pressure, central venous pressure
monitoring, and noninvasive pressure support ventilation. The
signals are relayed to a central monitoring station and the
nurse-to-patient ratio is 1:3. The ImCU infrastructure (beds,
technical resources and nursing staff) is shared by the Stroke
Unit and the Coronary Care Unit. These units also have
independent admission criteria and medical staff, and the
patients from these units were not taken into account for the
present study. The ImCU rounding team involves a nurse, the
hospital pharmacist, the ImCU resident, the specialist or
surgeon and the attending hospitalist. The hospitalist was
responsible for admission and discharge of all ImCU patients.
Admission and discharge criteria for the ImCU were set
according to previous guidelines defined by The American
College of Critical Care Medicine [14], and also served as
inclusion criteria for the present study. Exclusion criteria
included: age less than 18 years old, severe respiratory failure
at imminent risk of requiring intubation, status epilepticus, and
catastrophic brain illness. ImCU readmissions and patients
admitted for drug administration and desensitization, were
excluded from data analysis. Patients came from medical and
surgical wards, ICU, the operating room, and the emergency
room.
From April 2006 to April 2012, every consecutive patient
admitted to the ImCU was evaluated. Demographics, past
medical history, reasons for admission, physiological
parameters at the time of admission and during the first 24
hours of ImCU stay, laboratory variables and survival to
hospital discharge were prospectively recorded by the authors.
Patients with missing variables were also excluded from data
analysis.
The SAPS II and SAPS 3 scores with their respective
predicted mortality rates were calculated according to standard
coefficients [15,16]. We did not use the SAPS 3 customized
equation for Southern Europe, since previous studies showed
similar results using the general equation [17]. Data considered
for the calculation of SAPS 3 and SAPS II scores were
recorded within 1 hour and during the first 24 hours of ImCU
admission, respectively. In-hospital mortality was the end-point
of the study.
Ethics Statement
The study protocol was approved by the Institutional Review
Board (IRB) at the Clínica Universidad de Navarra (ref.
129/2010). The IRB waived the need for informed consent,
because it is an observational non-interventional cohort study
with prospectively collected data and retrospective analysis,
and also because it did not interfere with decisions related to
patient´s care. The study has been performed in accordance
with the ethical standards laid down in the 1964 Declaration of
Helsinki and its later amendments.
Statistical Analysis
Data were entered into a computer data base by the authors.
Statistical analysis was performed using SPSS for Windows,
version 15.0 (SPSS Inc, Chicago, IL). Continuous variables
were reported as mean ± standard deviation or median
(25%-75% interquartile range). For nonparametric measure of
statistical dependence of quantitative variables, we used
Spearman´s correlation coefficient. Categorical variables were
reported as absolute numbers (frequency percentages) and
analyzed by chi-square test. Validation of the prognostic scores
was assessed by standard tests to measure discrimination and
calibration. Discrimination was evaluated by calculating the
area under receiver operating characteristic curve (AUROC)
[18] and calibration with the Hosmer-Lemeshow goodness-of-fit
C test [19]. A high p value (> 0.05) would indicate a good fit for
the model. Calibration curves were constructed by deciles of
predicted mortality (x-axis) against observed mortality (y-axis).
Standardized mortality ratios (SMR) (ratio of observed to
expected deaths) with 95% confidence interval (95% CI) were
calculated for each model.
Results
During the study period, 938 patients were admitted in the
ImCU. Of these, 331 were excluded: 66 low risk patients (drug
administration and desensitization), 170 readmissions, and 95
patients for missing variables. Six hundred and seven (607)
patients were included for data analysis.
Patient characteristics, location prior to admission, surgical
status, coomorbidities and discharge location are described in
Table 1.
The mean age was 66 years with 61% male. The patients
were admitted from general ward (52%), emergency room
(25%), ICU (14%), operating room (6%) and a small number of
patients came from other hospital wards (3%). Reasons for
admission were essentially medical (87%), with respiratory
failure (33%) and sepsis (21%) as the most important causes
(Table 2). The average length of stay was 5±6 days.
The mean SAPS II and SAPS 3 of the cohort were 36.6±11.9
and 58.4±15.4 respectively, and the expected mortality derived
from these scores were 22.9 % and 35.6%. The observed in-
hospital mortality was 20.1% (122/607) resulting in a SMR of
0.87 (95% CI 0.73-1.04) for SAPS II and 0.56 (95% CI
0.47-0.67) for SAPS 3. Performances of the models are
presented in Table 3. Both scores showed acceptable
discrimination, with an AUROC of 0.76 (95% CI 0.71-0.80) for
SAPS II and 0.75 (95% CI 0.71-0.80) for SAPS3 (Figure 1).
Although both scores overpredicted mortality, SAPS II showed
better discrimination with results closer to the observed
mortality based on SMR. Nonetheless, the discrimination
performance assessed by AUROC did not show any
meaningful difference. Calibration curves are presented in
Figures 2 and 3. Both scores showed similar calibration
performance based on Hosmer-Lemeshow goodness of fit test:
(X2=12.9, p=0.113) for SAPS 2 and (X2=4.07, p=0.851) for
SAPS 3. Nonetheless, there is a non-significant trend for better
calibration performance for SAPS 3. We also established a
significant correlation between SAPS II and SAPS 3 in
predicting mortality (Rho 0.66 p < 0.01).
Discussion
Although intermediate care is worldwide recognized, there
are few studies in the last decades demonstrating the efficacy
SAPS II and SAPS 3 in Intermediate Care
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of these areas [3-12]. Moreover, there are only two previous
descriptions of SAPS II in this setting [11,12]. Auriant et al.
described in 1998, the performance of SAPS II in a cohort of
433 patients, showing good discriminant power (AUROC 0.85 ±
0.04) and calibration (C=2.4, p> 0.5). The SMR of the cohort
was 0.93, with an observed mortality of 8.1% (11). Our group
recently described similar results, with considerably higher
mortality rates in a cohort of 456 patients. The observed
mortality of the cohort was 20.6% with an expected mortality
derived from SAPS II calculation of 23.2% (SMR 0.89)
(AUROC 0.75, p< 0.001) [12].
To the best of our knowledge, this is the first external
validation study of the SAPS 3 score in ImCU population. In our
cohort, this relatively new score was not superior to its previous
version. Furthermore, the performance of SAPS II showed
better discrimination with results closer to the observed
mortality.
It is noteworthy the high risk of the patients in our study,
based on elevated SAPS II (36.6±11.9) and SAPS 3
(58.4±15.4) scores, with considerable expected mortality rates
22.9% and 35.6% respectively. The contribution of the
subgroup of oncologic patients (187/607), with advanced
Table 1. Patient Characteristics and Mortality (n 607).
Age (years) 66±14
Gender  
Male 373 (61.4%)
Female 234 (38.6%)
Location prior to admission:  
General Ward 315 (51.9%)
Emergency Room 151 (24.9%)
ICU 85 (14.0%)
Operating room 38 (6.3%)
Other hospital 18 (2.9%)
Coomorbidities in SAPS 3  
Immunosupression 235 (38.7%)
Metastatic cancer 140 (23.1%)
Haematological cancer 33 (5.4%)
Cirrhosis 42 (6.9%)
Chronic heart failure. NYHA IV 31 (5.1%)
Surgical status  
Planned 47 (7.7%)
Emergency 31 (5.1%)
Discharge Location  
Death 36 (5.9%)
General Ward 473 (78.0%)
ICU 75 (12.3%)
Home 5 (0.8%)
Other Hospital 18 (3.0%)
Death Location  
ImCU 36/607 (5.9%)
ICU 38/75 (50.7%)
General Ward 48/473 (10.1%)
ICU: Intensive Care Unit. SAPS 3: Simplified Acute Physiology Score 3.
ImCU: Intermediate Care Unit. NYHA IV: New York Heart Association Class IV.
doi: 10.1371/journal.pone.0077229.t001
disease (75%), and elevated SAPS II (42.1±12.2) and SAPS 3
(67.2±14.1) scores, could explain in part these findings. The
admission of these patients was required because their acute
disease needed close monitoring and was not due to ICU bed
restriction. However, in some cases, they were not candidates
for ICU admission due to the underlying disease, chronic
coomorbidities or advanced age.
Observed to expected mortality ratios (SMRs) have become
standard tools for assessing the impact of ICU-related
outcomes, including unit organization and management [20].
Therefore, it is very important to evaluate the performance of
Table 2. Reasons for ImCU admission and SMR based on
SAPS II and SAPS3.
Condition PatientsSAPS II SMR (95%CI) SAPS3
SMR
(95%CI)
Respiratory
failure 199
36.1 +/-
9.3
1.09
(0.81-1.44)
62.6 +/-
12.4
0.55
(0.4-0.73)
Sepsis 129 44.8 +/-13.8
0.71
(0.49-1.00)
67.6 +/-
12.8
0.52
(0.36-0.73)
Cardiovascular 82 35.3 +/-10.5
1.05
(0.64-1.64)
54.7 +/-
14.0
0.78
(0.48-1.21)
Perioperative 79* 29.1 +/-9.8
0.39
(0.10-0.89)
43.0 +/-
14.5
0.34
(0.09-0.74)
Complex
monitoring 51
33.4
+/-11.8
0.82
(0.34-1.58)
51.4 +/-
13.5
0.64
(0.28-1.21)
GI
complications 41
31.6 +/-
7.9
0.66
(0.17-1.48)
55.2 +/-
12.5
0.35
(0.09-0.81)
Neurologic 16 40.1 +/-8.9
1.59
(0.50-2.67)
61.0
+/-13.8
1.17
(0.36-1.96)
Liver Failure 10 41.0 +/-14.9
1.38
(0.35-2.96)
60.1
+/-20.2
0.96
(0.26-2.20)
ImCU: Intermediate Care Unit. SMR: Standardized mortality ratios.
SAPS: Simplified Acute Physiology Score. CI: Confidence interval.
*. The number of perioperative patients is not the same of the surgical status
subgroup described in Table 1 (n78), because some perioperative patients were
admitted for medical reasons and the surgery was not the main cause.
GI: Gastrointestinal complications.
doi: 10.1371/journal.pone.0077229.t002
Table 3. Performance of SAPS II and SAPS 3 scores in
ImCU.
 Score
Predicted
mortality SMR
Goodness-of-fit
C-test AUROC
  (SD) (95%CI) X2 p value (95%CI)
SAPS
II 36.6±11.9 22.9±18.5
0.87
(0.73-1.04) 12.9 0.113
0.76
(0.71-0.80)
SAPS
3 58.4±15.4 35.6±23.9
0.56
(0.47-0.67) 4.07 0.851
0.75
(0.71-0.80)
SAPS: Simplified Acute Physiology Score. ImCU: Intermediate Care Unit.
SD: standard deviation. SMR: Standardized mortality ratios. CI: Confidence
interval. AUROC: Area under receiver operating characteristic curve.
doi: 10.1371/journal.pone.0077229.t003
SAPS II and SAPS 3 in Intermediate Care
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prognostic models that are used to generate these data and
finally detecting potential biasses. Poor calibration and
mortality underestimation could prevent relevant comparisons
of data extracted from SMRs. In addition, external validation
studies are required before applying new scores to other case-
mixes. Soares and Salluh [21], found excellent discrimination
for SAPS II and SAPS 3 in a cohort of 952 oncologic patients
admitted to the ICU. The calibration of SAPS 3 and its
Figure 1.  Receiver operating characteristic curve (ROC) for SAPS II and SAPS 3.  
doi: 10.1371/journal.pone.0077229.g001
Figure 2.  Calibration curve based on the Hosmer and Lemeshow goodness-on-fit C test for SAPS II.  
doi: 10.1371/journal.pone.0077229.g002
SAPS II and SAPS 3 in Intermediate Care
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customized equation for Central and South American countries
in this cohort was appropriate, but the calibration of SAPS II
was poor. These results were in agreement with other reports
on the performance of SAPS II in ICU patients from European
countries, in which the model failed to adjust adequately for
differences in the case-mix profiles [22-24].
In the present study, we found similar calibration
performance of the models, with a non-significant trend for
better performance for SAPS 3, based on the Hosmer
Lemeshow goodness of fit C-test. However, it is surprising the
significant mortality overprediction based on the original SAPS
3 (SMR 0.56, 95% CI 0.47-0.67), and compared to SAPS II
(SMR 0.87, 95% CI 0.73-1.04, closer to unit).
Changes in case mix in critical care, has been one of the
reasons related to the poor calibration of SAPS II over time and
one of the arguments for the development of new generation
scores. It is possible that the oldest score avoids the potential
overfitting bias of SAPS 3, when the validation case mix cohort
is substantially different from the original study. Additionally,
recent external validation studies in ICU population, showed
similar results to ours, with both scores overpredicting
mortality, but SAPS 3 more than SAPS II [25,26].
These conflicting results emphasize the need to find more
reliable and accurate scores for intermediate care patients,
based on larger, prospective and well designed studies.
The present study provides an external validation of the
SAPS 3 score in intermediate care. However, several
limitations must be addressed. The case-mix of our cohort may
differ from that in other ImCUs, limiting the extrapolation of the
results to other populations. Case-mix differences between the
development cohort of SAPS 3 and our population could
deteriorate calibration and the ratios of observed to expected
mortality [27]. The small sample size derived from a single
center study, and even more restricted samples of various
subgroups of the population, could interfere with the evaluation
of the uniformity of fit among different expected mortality
subgroups. Moreover, the traditional calibration methods, such
as Hosmer-Lemeshow, only describe the deviations between
observed and expected mortality, without any description of the
direction, extent and risk subgroups affected by these
deviations. In the same way, they average the risk of patients
in each decile and do not use the whole information carried by
the individual patient [28,29].
Conclusions
This study highlights the importance of external validation of
prognostic scores in intermediate care, before the routine
application of new severity indexes.
SAPS II and SAPS 3 showed similar calibration performance
in ImCU, but SAPS II showed better discrimination in terms of
SMR.
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